Suggestion to CYDY: Recast LL as a gentic therapy.
Post# of 148170
Of course its irrelevant if CD12 is already good enough for EUA
Genetic therapies can achieve p values of .000001 on very small patient populations, like 20 patients.
Why? Because every patient recovers.
For covid, its possible that CCR5 double mutants (homozygous) don't get covid, just as they dont get HIV.
If true, all you need for FDA covid approval is 20 patients who all get better.
All you have to do is show, via RO testing, that as soon as you hit 98% or whatever RO then the patients will recover as long as they are not too far along in their illness.
Would really like to dose them intravenously instead of subQ because the RO would approach 100% more quickly.
But if you can figure out how to frame a trial where 100% recover, as in a genetic therapy, then you may only need 20 patients.